Moderna Inc. said its Omicron-tailored vaccines produced a better immune response against the BA.4/5 subvariants in a mid-to-late stage study, when given as a booster dose, compared with its original shot.
Tag Archive for: BA.4/5 subvariants
U.S. drugmaker Pfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot targeting the BA.4/5 subvariants produced a strong antibody response in humans than the original shot after one month.
